Ochromycinone

DB15644InvestigationalSmall molecule

Ochromycinone is under investigation in clinical trial NCT01047943 (STA-21 Topical Efficacy on Psoriasis).

Mechanism: Pharmacologically active on Thioredoxin reductase 1, cytoplasmic and Signal transducer and activator of transcription 3
Curator reviewed
Formula / weight: C₁₉H₁₄O₄ · 306.317 g/mol (avg)
Also known as: (+)-ochromycinone · (3s)-3.beta.-methyl-8-hydroxy-1,2,3,4,7,12-hexahydrobenzo(a)anthracene-1,7,12-trione · Benz(a)anthracene-1,7,12(2h)-trione, 3,4-dihydro-8-hydroxy-3-methyl-, (s)-
Code names: J655.169F · STA-21

Resolves to

Compound

Structure

InChIKeyZAWXOCUFQSQDJS-VIFPVBQESA-NSMILESC[C@@H]1CC(=O)C2=C3C(=O)C4=C(C(O)=CC=C4)C(=O)C3=CC=C2C1

Targets

What you can answer from here — as of July 08, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

7+ReferencesStructured and connected to the statements they support

Which drugs share a target with Ochromycinone, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.